23-Apr-2020 - Evotec SE

Evotec regains global rights to beta cell replacement therapy

Evotec continues development of the beta cell programme initially on its own

Evotec SE announced that it will regain global development and commercialisation rights to the iPSC-based programme for the treatment of diabetes developed under collaboration agreement with Sanofi. 

Evotec has built a unique platform for iPSC-based drug discovery and cell therapy covering the generation of iPS cell lines, up to cell manufacturing of various cell types for drug screening as well as GMP production of clinical material for cell therapies. Evotec produces human beta cells in islet-like clusters from a GMP-compliant iPS cell line in a scalable bioreactor format, with extensive quality control (“QC”) procedures. The beta cell programme has already achieved pre-clinical data demonstrating that they are functionally equivalent to primary human islets in their ability to normalise blood glucose levels in in vivo models over several months.

Evotec will continue the development of the beta cell programme on its own within its EVT Innovate initiative “QRbeta Therapeutics”. In parallel, Evotec will explore the best strategic options for further long-term development and commercialisation. An off-the-shelf beta cell therapy product has the potential to revolutionise the treatment of insulin-dependent diabetic patients and therefore could represent a major therapeutic opportunity.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Evotec and Sanofi have developed the beta cell replacement therapy programme since 2015 in a highly productive partnership. During this time, we have made tremendous progress towards bringing a potentially game-changing treatment option to the clinic. We would like to thank Sanofi for the collaboration and its contributions. Regaining full control of this innovative and promising programme to treat diabetes is of great value for Evotec. While we are continuing to move this programme forward, we are exploring partnering options to bring this therapy to patients.”

Facts, background information, dossiers
More about Evotec
  • News

    Drug discovery with artificial intelligence

    Evotec SE announced that the Company has participated in the Series C funding round of Exscientia, the Artificial Intelligence (AI)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, ... more

    Evotec to collaborate with Ology Bioservices on antibodies against Coronavirus

    Evotec SE announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into a partnership with Ology Bioservices, Inc. (Ology Bio) for the evaluation and analytical characterisation of antibodies against SARS-CoV-2. This work falls under a contract awarded to Ology ... more

    Evotec and Takeda enter into multi-year gene therapy research alliance

    Evotec SE announced that Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s growing number of research stage gene therapy discovery programmes. Under the alliance, Evotec will support multiple Takeda programmes targeting cond ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more